A phase 3, open-label, multicenter, randomized study to compare the efficacy and safety of the Zevalin (ibritumomab tiuxetan) [ibritumomab tiuxetan Y-90] therapeutic regimen following cyclophosphamide, vincristine, prednisone, and rituximab (R CVP) with R CVP alone in high risk subjects with previously untreated CD20 positive non Hodgkin's lymphoma (NHL)

Trial Profile

A phase 3, open-label, multicenter, randomized study to compare the efficacy and safety of the Zevalin (ibritumomab tiuxetan) [ibritumomab tiuxetan Y-90] therapeutic regimen following cyclophosphamide, vincristine, prednisone, and rituximab (R CVP) with R CVP alone in high risk subjects with previously untreated CD20 positive non Hodgkin's lymphoma (NHL)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Cyclophosphamide; Prednisone; Rituximab; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Biogen; Cell Therapeutics; Spectrum Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2008 Cell Therapeutics reported as trial affiliate and sponsor as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Primary outcome changed from progression-free survival to safety as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Actual patient number (26) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top